Table 2. Distribution of subjects who were candidates for lipid-lowering drug therapy for primary prevention (age 20–79 years).
| Total | Men | Women | |
|---|---|---|---|
| (n = 5,837) | (n = 4,209) | (n = 1,628) | |
| N (%) | N (%) | N (%) | |
| 2013 ACC/AHA guideline | |||
| LDL-C ≥ 190 mg/dl | 90 (1.5) | 46 (1.1) | 44 (2.7) |
| Diabetes & 40–75 & LDL 70–189 mg/dL | 663 (11.4) | 558 (13.3) | 105 (6.4) |
| No Diabetes & 40–75 & LDL 70–189 mg/dL& ASCVD≥ 7.5% | 1210 (20.7) | 1134 (26.9) | 76 (4.7) |
| Total candidates | 1963 (33.6) | 1738 (41.3) | 225 (13.8) |
| 2004 ATP III guideline | |||
| CHD risk equivalents * & LDL-C≥ 100 mg/dl | 597 (10.2) | 510 (12.1) | 87 (5.3) |
| No Diabetes & CHD risk factor ≥ 2 | |||
| CHD risk 10–20% & LDL-C ≥ 130 mg/dl | 263 (4.5) | 258 (6.1) | 5 (0.3) |
| CHD risk <10% & LDL-C ≥ 160 mg/dl | 49 (0.8) | 35 (0.8) | 14 (0.9) |
| No CHD & no Diabetes & CHD risk factor 0–1 | |||
| LDL-C ≥ 190 mg/dl | 46 (0.8) | 15 (0.4) | 31 (1.9) |
| Total candidates | 955 (16.4) | 818 (19.4) | 137 (8.4) |
| Subjects eligible for statins by 2013 ACC/AHA guideline only | 1110 (19.0) | 1013 (24.1) | 97 (6.0) |
| Subjects eligible for statins by 2004 ATP III guideline only | 102 (1.7) | 93 (2.2) | 9 (0.6) |
| Subjects eligible for statins by both guidelines | 853 (14.6) | 725 (17.2) | 128 (7.9) |
ACC/AHA, American College of Cardiology / American Heart Association; LDL-C, low-density lipoprotein cholesterol; ASCVD, atherosclerotic cardiovascular disease; ATP, Adult Treatment Panel; CHD, coronary heart disease.
*Diabetes or CHD risk factor ≥ 2 & CHD risk >20%.